TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00785772

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gabapentin
Description: 100-200mg once a day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gabapentin
Description: 200-500mg once a day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gabapentin
Description: 400-1000mg (200-500 mg twice a day)
Study: NCT03470987

Intervention type: PROCEDURE
Intervention: Phase I Periodontal therapy
Description: Oral hygiene instuction, scaling and root planning

Intervention type: PROCEDURE
Intervention: Phase I Periodontal therapy
Description: Oral hygiene instuction, scaling and root planning

Intervention type: PROCEDURE
Intervention: Phase I Periodontal therapy
Description: Oral hygiene instuction, scaling and root planning

Intervention type: PROCEDURE
Intervention: Phase I Periodontal therapy
Description: Oral hygiene instuction, scaling and root planning

Intervention type: DIETARY_SUPPLEMENT
Intervention: Metabolic control
Description: Calorie restricted diet

Intervention type: DIETARY_SUPPLEMENT
Intervention: Metabolic control
Description: Calorie restricted diet
Study: NCT02967016

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Actigraph
Description: following delivery a ActiGraph will be offered to patients to track their steps

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Actigraph
Description: following delivery a ActiGraph will be offered to patients to track their steps
Study: NCT01391442

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: blood and urine samples
Description: 58 ml of blood 120 ml of urine

Intervention type: GENETIC
Group type: OTHER
Intervention: blood sample
Description: 11 ml of blood

Intervention type: OTHER
Group type: OTHER
Intervention: cardiovascular assessment
Description: echography, echodoppler, measure of blood pressure...

Intervention type: OTHER
Group type: OTHER
Intervention: Stanislas ancillary study : MRI examination with GRICS technique
Study: NCT03784963

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omega 3 fatty acids
Description: Patients will receive 4 grams fish oil once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omega 3 fatty acids
Description: Patients will receive 4 grams fish oil once daily

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Standard of care

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Standard of care
Study: NCT03176030

Intervention type: DIETARY_SUPPLEMENT
Intervention: Fortified Foods
Description: The intervention under study is the provision of between-meal fortified foods (enhanced with protein, energy, and micronutrients) and meal supplementation where meals are poorly consumed. Foods will include both savory and sweet foods with different flavors. Foods will be matched as closely as possible in protein and energy and are calculated to provide typically 210 kcal and 5g protein per item. The volume / weight of the foods are standardized to be of relatively small portion size, such as 100 ml for ice-creams, 40 g for cakes and biscuits, and 100 ml for soup. Some of the products will be supplemented with micronutrients particularly needed by older adults, such as Vitamins (C, D, folic acid, B2, B6) and calcium at one third of the Dietary Reference Values (DRV) per portion. The aim is to achieve a daily consumption of two additional fortified food items.
Study: NCT01362491

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibuprofen Sodium
Description: Single-dose of ibuprofen sodium tablets (equal to 400 mg ibuprofen)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard Ibuprofen
Description: Single-dose of standard ibuprofen tablets (400mg)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single-dose of placebo
Study: NCT04653350

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High Intensity Exercises
Description: Supervised High intensity Progressive Resistance Training, High intensity weightbearing/Impact exercises and High challenging Balance Training will be given. 2 times/week for 40-50minutes session progressively over the duration of 8 months.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: General Exercises
Description: Supervised general fitness exercises including general body stretches, treadmill walking, mild to moderate intensity progressive resistance training \& balance exercises will be given. 2 times/week for 40-50minutes session progressively over the duration of 8 months
Study: NCT02491736

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketoprofen
Description: 2.5% ketoprofen gel

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo gel
Study: NCT01090024

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 671800
Description: BI 671800

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 671800
Description: BI 671800

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 671800
Description: BI 671800

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo matching BI 671800
Study: NCT01159158

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nateglinide
Description: Nateglinide Tablets 120 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nateglinide
Description: Nateglinide Tablets 120 mg
Study: NCT03667547

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Raltegravir
Description: Raltegravir 600 mg tablet
Study: NCT01779882

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Busulfan-Cyclophosphamide as Conditioning Regimen before Allogeneic Hematopoietic Stem Cell Transplantation
Description: Test the hypothesis, that the order of application of Busulfan (BU) and Cyclophosphamide (CY) has an impact on toxicity after allogeneic Hematopoietic stem cell transplantation (HSCT) and that CY-BU reduces liver toxicity compared to BU-CY.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide-Busulfan as Conditioning Regimen before Allogeneic Hematopoietic Stem Cell Transplantation
Description: Test the hypothesis, that the order of application of Busulfan (BU) and Cyclophosphamide (CY) has an impact on toxicity after allogeneic Hematopoietic stem cell transplantation (HSCT) and that CY-BU reduces liver toxicity compared to BU-CY.
Study: NCT04428554

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Experimental arm
Description: Consolidative radiotherapy (pelvic irradiation and/or metastases irradiation) + standard of care +/- previous transurethral resection of bladder tumor
Study: NCT04090320

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CATERPILLAR™ Arterial Embolization Device
Description: Placement of the CATERPILLAR™ Arterial Embolization Device for patients requiring arterial embolization in the peripheral vasculature.
Study: NCT02037243

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard Public Health Intervention with Water Treatment
Description: Compound level meeting

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard Public Health Intervention with Water Treatment
Description: Compound level meeting

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard Public Health Intervention with Water Treatment & Hand Washing
Description: Compound level meeting

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard Public Health Intervention with Water Treatment & Hand Washing
Description: Compound level meeting

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard Public Health Intervention with Water Treatment & Hand Washing
Description: Compound level meeting

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Disgust and Shame Based Intervention with Water Treatment
Description: Compound level meeting

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Disgust and Shame Based Intervention with Water Treatment
Description: Compound level meeting

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Disgust and Shame Based Intervention with Water Treatment & Hand Washing
Description: Compound level meeting

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Disgust and Shame Based Intervention with Water Treatment & Hand Washing
Description: Compound level meeting

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Disgust and Shame Based Intervention with Water Treatment & Hand Washing
Description: Compound level meeting
Study: NCT02932293

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SOF+DCV+SMV
Description: Sofosbuvir (SOF) 400 mg tablet administered orally once daily; Daclatasvir (DCV) 60 mg tablet administered orally once daily; Simeprevir (SMV) 150 mg tablet orally once daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SOF+DCV+SMV
Description: Sofosbuvir (SOF) 400 mg tablet administered orally once daily; Daclatasvir (DCV) 60 mg tablet administered orally once daily; Simeprevir (SMV) 150 mg tablet orally once daily.
Study: NCT00470795

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acupuncture
Description: acupuncture treatment (or placebo), 20 minute treatment each; twice weekly for four weeks (total of eight treatments). repeat treatment schedule following crossover (placebo-treatment)

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: placebo/sham acupuncture
Description: acupuncture at sham points without skin penetration
Study: NCT02491931

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Supplement/placebo intake
Description: Patients will receive either GLN or placebo prior to cardiovascular surgery under extracorporeal circulation, during 3 days and one final dose 4 hours prior to anesthesia.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Supplement/placebo intake
Description: Patients will receive either GLN or placebo prior to cardiovascular surgery under extracorporeal circulation, during 3 days and one final dose 4 hours prior to anesthesia.
Study: NCT02716909

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cervical pessary
Description: The cervical pessary is a silicone device that has been used to prevent SPTB Pessary will be placed between 18 and 23 6/7 weeks gestation, and will be removed during the 37th week of pregnancy (or earlier, if indicated)
Study: NCT03007459

Intervention type: OTHER
Intervention: Psychological health
Description: Observing and measuring baseline, and changes in, psychological health through a fitness contest preparation period

Intervention type: OTHER
Intervention: Psychological health
Description: Observing and measuring baseline, and changes in, psychological health through a fitness contest preparation period

Intervention type: OTHER
Intervention: Physiological health
Description: Observing and measuring baseline, and changes in, physiological health through a fitness contest preparation period

Intervention type: OTHER
Intervention: Physiological health
Description: Observing and measuring baseline, and changes in, physiological health through a fitness contest preparation period
Study: NCT02359838

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Baseline Geriatric Screening/Assessment
Description: All patients receive baseline geriatric screening/assessment by a research assistant to determine frailty status.

Intervention type: OTHER
Group type: OTHER
Intervention: Baseline Geriatric Screening/Assessment
Description: All patients receive baseline geriatric screening/assessment by a research assistant to determine frailty status.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Geriatrician Co-Management
Description: A board-certified geriatrician embedded in the oncology clinic will co-manage patients randomized to this arm.
Study: NCT03797235

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Dominant Arm
Description: The volume of local anesthetic used for the block of the ulnar and median nerve will be 5 times the estimated 95% effective dose (ED 95 ) of LA needed to block the nerve relative to the nerve cross-sectional area. The ED 95 for the ulnar nerve has been elucidated to be 0,11ml/mm2. The same ED 95 will be used for the median nerve.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Non-dominant arm
Description: The volume of local anesthetic used for the block of the ulnar and median nerve will be 5 times the estimated 95% effective dose (ED 95 ) of LA needed to block the nerve relative to the nerve cross-sectional area. The ED 95 for the ulnar nerve has been elucidated to be 0,11ml/mm2. The same ED 95 will be used for the median nerve.
Study: NCT03121183

Intervention type: DEVICE
Intervention: Laser sheath
Description: Patients who have undergone an extraction of implantable pacemaker or defibrillator leads whatever the indication for the period march 2015-2017

Intervention type: BEHAVIORAL
Intervention: Implantable Cardiac Device lead extraction
Description: Patients who have undergone an extraction of implantable pacemaker or defibrillator leads whatever the indication for the period march 2015-2017
Study: NCT03987412

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle intervention with APP
Description: The face to face education class will be conducted by an obstetrician, an endocrinologist and a nutritionist together. Then the lifestyle intervention will be launched by an APP that installed in participants' private mobile phones, including nutrition, exercise and phycological support. Nutrition guidance is conducted according to the Chinese Dietary Guide, Chinese and international guidelines of gestation diabetes management. Exercise support is given based on the Guidelines for National Fitness of China, Chinese and international guidelines of gestation diabetes. Phycological support is given by sending education articles on mental health. Participants are encouraged to update data about their diet, exercise and body weight through the APP, and based on the data investigators will individualize the suggestions.
Study: NCT02379741

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ADC-1013
Description: Agonistic human monoclonal IgG1 anti-CD40 antibody

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ADC-1013
Description: Agonistic human monoclonal IgG1 anti-CD40 antibody
Study: NCT04517617

Intervention type: OTHER
Intervention: The level of air pollution
Description: The intervention measure is the level of air pollution, it is a non-human interventional measure based on the weighted average of various air pollutants monitored by air pollution monitoring stations during different period of pregnancy.he perinatal period.
Study: NCT03825601

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: PET with [11C]Flumazenil
Description: 7T MRI sequences : TSE, T2w FLAIR GRE-T2\* and DIR 3T MRI sequences: T1, T2, T1 with gadolinium, magnetization transfer, diffusion weighted, resting state fMRI.

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: PET with [11C]Flumazenil
Description: 7T MRI sequences : TSE, T2w FLAIR GRE-T2\* and DIR 3T MRI sequences: T1, T2, T1 with gadolinium, magnetization transfer, diffusion weighted, resting state fMRI.
Study: NCT03587675

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: EVH test
Study: NCT01951014

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Social Media Education
Description: Health messages provided via a private Facebook group and cellular text messages will be provided across gestation.
Study: NCT03293095

Intervention type: PROCEDURE
Intervention: Standard Care
Description: The guidelines for the management according to the musculoskeletal disorder in primary care will be the treatment guidelines for the Standard Care.
Study: NCT04759287

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: C-MAC VS
Description: The first group (VS group) will include patients undergoing awake intubation using the C-MAC VS

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: flexible fibreoptic bronchoscope
Description: The second control group (FOB group) will include patients undergoing awake intubation using the flexible fibreoptic bronchoscope.
Study: NCT01998477

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TIVc
Description: Madin Darby Canine Kidney (MDCK) cell culture derived subunit influenza vaccine TIVc contained the purified viral envelope glycoproteins, hemagglutinin (HA) and neuraminidase (NA) derived from 3 strains (including HA for each strain \[A/H1N1-like, A/H3N2-like, and B-like\]) intramuscular (IM) injection recommended by the WHO for the 2013-2014 influenza season in the Northern Hemisphere

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: TIV
Description: A conventional egg derived subunit influenza vaccine (TIV) contained the purified viral envelope-glycoproteins, HA and NA derived from 3 strains (including HA for each strain \[A/ H1N1-like, A/H3N2-like, and B-like\]) IM injection recommended by the WHO for the 2013-2014 influenza season in the Northern Hemisphere.
Study: NCT00780585

Intervention type: DRUG
Intervention: SCH 900460
Description: Subjects who participated in previous trials of Org 24448 (SCH 900460)
Study: NCT04357379

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: IQOS
Description: Participants will try an IQOS product and then take home the IQOS to sample for one week.
Study: NCT01051375

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psychoeducational Workshop and telephone support
Description: The intervention involves completion of a single workshop (delivered by a psychiatrist and adolescent health physician), provision of psycho educational materials, and regular telephone support with a specially trained nurse-coordinator to parents of youth on our waiting list.
Study: NCT04015947

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CelluTome® Epidermal Harvesting System
Description: split-thickness skin grafts from a matched bone marrow donor using the CelluTome® Epidermal Harvesting System
Study: NCT02030145

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Compressive Thoracic Lymphatic Pump
Description: This technique is a modification of the Classic Thoracic Lymphatic Pump where some pressure is maintained on the chest wall at the end of each exhalation and at the end of the third or fourth breathing cycle, during the inhalation phase, the hands are slowly removed from the chest wall, gradually releasing pressure on the chest without causing a sudden change in intrathoracic pressures.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Compressive Thoracic Lymphatic Pump
Description: This technique is a modification of the Classic Thoracic Lymphatic Pump where some pressure is maintained on the chest wall at the end of each exhalation and at the end of the third or fourth breathing cycle, during the inhalation phase, the hands are slowly removed from the chest wall, gradually releasing pressure on the chest without causing a sudden change in intrathoracic pressures.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Classic Thoracic Lymphatic Pump
Description: This technique is well described in Chapter 68 of the Foundations for Osteopathic Medicine, 2nd Edition.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Classic Thoracic Lymphatic Pump
Description: This technique is well described in Chapter 68 of the Foundations for Osteopathic Medicine, 2nd Edition.
Study: NCT01574313

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: stellate ganglion block
Description: stellate ganglion block

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.25mg, fludiazine
Description: 0.25mg of erispan@ (fludiazine), p.o. one dose only.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 25mg cephadol@ (diphenidol)
Description: 25mg cephadol@ (diphenidol) p.o. one dose only.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 200mg kentons@ (tocopherol nicotinate).
Description: 200mg kentons@ (tocopherol nicotinate) p.o. one dose only.
Study: NCT04611711

Intervention type: DRUG
Group type: OTHER
Intervention: decitabine＋ TQB2450 injection
Description: Real low-dose epigenetics drugs (decitabine) can reverse the resistance of PD-1 inhibitors by re-regulating the immune microenvironment.~TQB2450 is a humanized monoclonal antibody targeting PD-L1, which prevents PD-L1 from binding to the PD-1 and B7.1 receptors on the surface of T cells, so as to restore the activity of T cells and thereby enhance the immune response, and has the potential to treat various types of tumors.

Intervention type: DRUG
Group type: OTHER
Intervention: decitabine＋ TQB2450 injection＋Anlotinib
Description: Real low-dose epigenetics drugs (decitabine) can reverse the resistance of PD-1 inhibitors by re-regulating the immune microenvironment.~TQB2450 is a humanized monoclonal antibody targeting PD-L1, which prevents PD-L1 from binding to the PD-1 and B7.1 receptors on the surface of T cells, so as to restore the activity of T cells and thereby enhance the immune response, and has the potential to treat various types of tumors.~Anlotinib Hydrochloride is a multi-target receptor tyrosine kinase inhibitor with significant inhibitory activity against angiogenesis related kinases (VEGFR1/2/3, FGFR1/2/3, etc.) and other tumor cell proliferation-related kinases (PDGFR /, C-Kit, RET, etc.), which can play a dual role in anti-tumor angiogenesis and tumor growth inhibition.
Study: NCT02519751

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: D3 Creatine
Description: One dose of D3 Creatine (60mg capsule) given orally on Day 1

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Creatine
Description: Participants will consume an individual dosed level of creatine, based on their estimated muscle mass in doses of 0.03, 0.035, 0.04, 0.045 g.kg.Lean mass/day, increasing on a weekly basis. Final dose of 0.05 g.kg.Lean mass/day is then maintained throughout the study.